HBV Management in 2012… Where Are We Heading?

Management of Chronic Hepatitis B

Unanswered Questions from the REVEAL

27 Year Follow-up on Maori population in New Zealand with Genotype D

9 Year Natural History Study of CHB Patients in the United States

Independent Factors Associated with Disease Progression and HCC

Patients Who Developed Serious Liver-related Complicationsa May Be Excluded from Treatment by Current Guidelines/Algorithms

Evaluate CHB Patients for Treatment

Liver Biopsy for Treatment Candidate Selection

Fibro Test: Indeterminate rates ~ 50%

FibroScan®

Evaluation on Patients in the Gray Zone

Recommendations for First-Line Therapy in Patients Without Cirrhosis

Change in Ishak Scores at Year 3-7 of Entecavir Therapy by Baseline Fibrosis Score

Suboptimal Response to Entecavir Therapy

Change in Ishak Scores at Year 5 of Tenofovir Therapy by Baseline Fibrosis Score

No Patient with Persistent Viremia During Year 5 Analysis for Tenofovir Therapy

Combining ETV and TDF vs. ETV Therapy

HBsAg Loss in HBeAg-Positive and HBeAg-Negative Patients

Phase I/II Study of a Potent HBsAg Release Inhibitor: REP 9AC

REP 9AC Study Results

Immunophrophylaxis failure rates of the infants born to mothers with different virologic features

Lamivudine Therapy for the Prevention of Vertical Transmission During Pregnancy

Elective Cesareans Delivery and Risk of Perinatal Transmission of HBV

Where Are We Heading?

Thank You!